The effect of anti-tumor necrosis factor (TNF)-alpha therapy with etanercept on endothelial functions in patients with rheumatoid arthritis; [Romatoid artrit'li hastalarda etanercept ile yapilan anti-tümör nekroz faktör (TNF)-alfa tedavisinin endotel fonksiyonlari üzerine etkisi]

Simple item page
dc.contributor.authorTikiz H.
dc.contributor.authorArslan Ö.
dc.contributor.authorPirildar T.
dc.contributor.authorTikiz C.
dc.contributor.authorBayindir P.
dc.date.accessioned2024-07-22T08:20:58Z
dc.date.available2024-07-22T08:20:58Z
dc.date.issued2010
dc.description.abstractObjective: To investigate the effects of tumor necrosis factor (TNF)-〈 antagonism with etanercept (ENC) on endothelial functions in patients with active rheumatoid arthritis (RA). Methods: A total of 21 patients with RA were enrolled in this prospective study. Eleven of them (8 women, 3 men mean age 47.0±10.1 years) with high disease activity despite the conventional treatment were assigned to Group 1 and were given ENC treatment twice a week (25 mg SC injection) for 12 weeks. Ten patients with RA (8 women, 2 men mean age 55.0±6.4 years) under conventional methotrexate and prednisone therapy were assigned as Control group (Group 2). Endothelium-dependent and -independent vasodilator responses of the brachial artery were assessed by high-resolution ultrasound. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were also measured at baseline and at the post treatment period. Mann-Whitney U and Wilcoxon tests were used to compare the data and correlation analysis was performed using Pearson correlation test. Results: Endothelium-dependent vasodilatation improved from 5.2±0.8% to 7.9±1.3% (p=0.04) in ENC group, while no significant change was observed in the control group (from 6.6±1.1% to 7.0±1.8% p=0.67). No significant changes were found in endothelium-independent vasodilatation and baseline brachial artery diameters in both groups. A significant reduction in ESR and CRP were observed in patients receiving ENC (from 16.2±6.8 to 9.2± 5.1 mm/h, p=0.003 and from 14.68±3.4 to 9.25± 3.7 mg/L, p=0.003, respectively). Conclusion: Treatment with ENC for 12 weeks significantly improved endothelial function in patients with active RA compared to those under conventional therapy. The findings of the present study support the hypothesis that the use of TNF-〈 blockers in patients with active RA may reduce the high incidence of cardiovascular complications. (Anadolu Kardiyol Derg 2010; 10: 98-103) © Copyright 2010 by AVES Yayincilik Ltd.
dc.identifier.DOI-ID10.5152/akd.2010.031
dc.identifier.issn13028723
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/18378
dc.language.isoEnglish
dc.subjectAdult
dc.subjectAntirheumatic Agents
dc.subjectArthritis, Rheumatoid
dc.subjectBlood Sedimentation
dc.subjectBrachial Artery
dc.subjectC-Reactive Protein
dc.subjectCardiovascular Diseases
dc.subjectEndothelium, Vascular
dc.subjectFemale
dc.subjectHumans
dc.subjectImmunoglobulin G
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectProspective Studies
dc.subjectReceptors, Tumor Necrosis Factor
dc.subjectTreatment Outcome
dc.subjectTumor Necrosis Factor-alpha
dc.subjectVasodilation
dc.subjectC reactive protein
dc.subjectdisease modifying antirheumatic drug
dc.subjectetanercept
dc.subjectmethotrexate
dc.subjectprednisone
dc.subjecttumor necrosis factor alpha inhibitor
dc.subjectantirheumatic agent
dc.subjectC reactive protein
dc.subjectimmunoglobulin G
dc.subjectTNFR Fc fusion protein
dc.subjectTNFR-Fc fusion protein
dc.subjecttumor necrosis factor alpha
dc.subjecttumor necrosis factor receptor
dc.subjectadult
dc.subjectartery diameter
dc.subjectarticle
dc.subjectcardiovascular effect
dc.subjectclinical article
dc.subjectclinical evaluation
dc.subjectclinical trial
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectcorrelational study
dc.subjectdisease activity
dc.subjectdose response
dc.subjectdrug effect
dc.subjectechography
dc.subjecterythrocyte sedimentation rate
dc.subjectfemale
dc.subjecthuman
dc.subjectmale
dc.subjectoptimal drug dose
dc.subjectoutcome assessment
dc.subjectrheumatoid arthritis
dc.subjecttreatment duration
dc.subjectvasodilatation
dc.subjectblood
dc.subjectbrachial artery
dc.subjectcardiovascular disease
dc.subjectdrug antagonism
dc.subjectmetabolism
dc.subjectmiddle aged
dc.subjectphysiology
dc.subjectprospective study
dc.subjecttreatment outcome
dc.subjectvascular endothelium
dc.titleThe effect of anti-tumor necrosis factor (TNF)-alpha therapy with etanercept on endothelial functions in patients with rheumatoid arthritis; [Romatoid artrit'li hastalarda etanercept ile yapilan anti-tümör nekroz faktör (TNF)-alfa tedavisinin endotel fonksiyonlari üzerine etkisi]
dc.typeArticle

Files

Collections

Scopus Koleksiyonu